Life Science News

LevelJump Healthcare Corp. a Canadian leader in B2B telehealth solutions, is pleased to announce new additions to its board of directors and its advisory board.Gary Prihar - DirectorMr. Prihar Brings Extensive Health Care Clinic Experience to Spearhead Advanced Training in Outreach, Telemedicine, and Expansive Growth Strategies.Bringing comprehensive and advanced industry knowledge to the organization, with the ...

LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("Leveljump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce new additions to its board of directors and its advisory board.

Gary Prihar - Director

Mr. Prihar Brings Extensive Health Care Clinic Experience to Spearhead Advanced Training in Outreach, Telemedicine, and Expansive Growth Strategies.

Bringing comprehensive and advanced industry knowledge to the organization, with the critical lens of CPA and CA designations, Mr. Prihar's experience empowers management with an intimate understanding of the dynamics that create a platform for highly successful interactions between provider and recipient.

Prior to being appointed to Board of Directors, Gary Prihar's track record shows a legacy of commitment to strategic growth, with hallmarks of industry leadership and collaboration, including the President and Co-Founder of Move Health & Wellness, the President, CFO & Co-Founder of Viva Care Medical and Telehealth Group as well as Board member and senior consultant for Lyte Medical.

Richard Jagodnik - Director

Richard is an alumni of the John Molson School of Business, at Concordia University, with a major in Accounting and received his CA designation in 1994. He has had over 10 years of audit experience, followed by 20 years of being a controller and CFO for private corporations with annual revenues ranging from $20 million to in excess of $100 million.

Jackie Glazer - Director

Jackie has over 20 years of experience as a business partner and advisor on leadership teams in a number of industries. Jackie has held roles in public and private companies, leading finance and operations through periods of growth through acquisitions, as well as organically. Jackie has managed recapitalizations of companies at various stages of development. She has experience spanning financial services, healthcare and manufacturing with a deep understanding of business strategy and management. Jackie holds a CPA, CA designation earned in 1998 after graduating from the University of British Columbia.

Dr. Jonathan Chung, M.D,FRCPC - Advisory Board

Dr. Chung is a radiologist with expertise in interventional radiology and teleradiology who specializes in US, CT and MRI modalities. Dr. Chung has extensive experience working in hospitals, acting as chief resident, and also serves as a lead radiologist for CTS. A graduate of Dalhousie Medical School, Dr. Chung completed his radiology residency at Western University and Interventional Fellowship at UHN. Dr. Chung can assist Leveljump with radiology workflow, medical protocols, radiology practice expansion and other medical areas as needed.

"We are very pleased to welcome a number of new faces with extensive business, accounting and healthcare experience to our board of directors and our advisory board," Mitch Geisler, CEO. "We feel that the new board, through its diversity and depth of business experience will be able to guide the Company through its next phase of growth."

The company also announces that Mr. Jeff Stevens and Ms. Sandy Hall have resigned from the Company's board of directors.

The Company would like to thank them for their services to the board during the going public process and wish them well in their future endeavors.

About Leveljump Healthcare

LevelJump Healthcare Corp., (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) is a healthcare company with a focus on profitable telehealth solutions as well as primary care services in radiology. The Company's subsidiary, CTS, provides off-site radiology readings for hospital emergency rooms and is a leader in the teleradiology space in Ontario. As part of our growth strategy, we are acquiring healthcare companies that have strong revenue and cash flow, with room for organic growth.

ON BEHALF OF THE BOARD OF DIRECTORS OF
LevelJump Healthcare Corp.

Mitchell Geisler, Chief Executive Officer
info@leveljumphealthcare.com
(833) 840-2020

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business plans and the outlook of the Company's industry. Although the Company believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this release and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by applicable securities laws. The Company undertakes no obligation to comment on analyses, expectations or statements made by third parties in respect of the Company, Canadian Teleradiology Services, Inc., their securities, or their respective financial or operating results (as applicable).

Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities being offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor in any other jurisdiction.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/106906

News Provided by Newsfile via QuoteMedia

Medtronic announces results showing meaningful pain relief using DTM Spinal Cord Stimulation endurance therapy

DTM™ SCS endurance therapy enables long-lasting recharge-free performance on Vanta™ and 5-minute recharge on Intellis™ neurostimulators

- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced three-month results from an on-label, prospective, multi-center study 1 showing meaningful pain relief using DTM™ SCS endurance therapy, a modified, lower-energy variation of the company's Differential Target Multiplexed™ (DTM) Spinal Cord Stimulation (SCS) therapy for chronic overall, back or leg pain. At 3 months, patients treated with DTM SCS endurance therapy reported meaningful pain relief as measured by a 3.9 cm reduction in overall pain on the 10 cm Visual Analog Scale (VAS) 2 . Patients also reported an average 4.3 cm decrease in back pain, and an average 5.0 cm decrease in leg pain.

Keep reading... Show less

Bausch + Lomb Corporation Files Registration Statement and Preliminary Prospectus for Proposed Initial Public Offering

- Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health") announced today that, in connection with its previously announced intention to separate its eye health business, its wholly owned subsidiary, Bausch + Lomb Corporation ("Bausch + Lomb"), has publicly filed a Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") and a preliminary base post-receipt pricing procedure ("PREP") prospectus with the securities regulatory authorities in each of the provinces and territories of Canada (other than Quebec ) ("Canadian Regulators") relating to a proposed initial public offering ("IPO") of Bausch + Lomb's common shares concurrently in the United States and Canada . All of the shares being offered will be sold by a wholly owned subsidiary of Bausch Health. The number of common shares to be offered and the price range for the IPO have not yet been determined.

Morgan Stanley and Goldman Sachs & Co. LLC are acting as joint lead book-running managers for the IPO. J.P. Morgan, Citigroup, Barclays, BofA Securities, Guggenheim Securities, Jefferies, Evercore ISI, Wells Fargo Securities and Deustche Bank Securities are acting as joint book-running managers for the IPO, and DNB Markets, HSBC and Truist Securities are acting as co-managers for the IPO.

Keep reading... Show less

Medtronic announces schedule for presentations at the 2022 North American Neuromodulation Society Meeting

Sessions will include DTM™ SCS endurance therapy 3-month outcomes for patients with chronic back and leg pain

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced its schedule for presentations at the 25th Annual North American Neuromodulation Society meeting, taking place January 13-15, 2022 in Orlando, Florida . Medtronic therapies and technologies will be represented as part of 23 podium and poster presentations. The company will also welcome guests to booth #404 featuring an innovation suite and opportunities to learn from Medtronic scientists and engineers about the new Vanta™ recharge-free neurostimulator, as well as a new modified energy variation of Differential Target Multiplexed™ (DTM) Spinal Cord Stimulation known as DTM™ SCS endurance therapy. Medtronic will also showcase its targeted drug delivery options for patients with chronic pain.

Keep reading... Show less

Abbott Receives U.S. FDA Clearance for New Cardiac Mapping System to Improve How Doctors Treat Abnormal Heart Rhythms

- Abbott (NYSE: ABT) today announced it has received clearance from the U.S. Food and Drug Administration for the EnSite™ X EP System with EnSite Omnipolar Technology (OT), a new cardiac mapping platform available in the U.S. and across Europe that is designed to help physicians better treat abnormal heart rhythms, also known as cardiac arrhythmias. Designed with input from electrophysiologists from around the world, the system creates highly detailed three-dimensional maps of the heart to help physicians identify and then treat areas of the heart where abnormal rhythms originate.

"More patients than ever before are benefitting from ablation to treat abnormal heart rhythms, and Abbott's new EnSite X System with EnSite OT, utilizing Advisor HD Grid catheter, embodies the latest innovation available to support the treatment of complex and challenging cardiac arrhythmias," said Amin Al-Ahmad , M.D., a clinical cardiac electrophysiologist with Texas Cardiac Arrhythmia at St. David's Medical Center in Austin, Texas . "To continue improving outcomes for our patients, we need a system with speed, stability and accuracy. Abbott has provided us with a system that not only supports safe and effective treatment, but enhances the accuracy of maps, allowing for a clearer understanding of what is going on in the heart and what areas need to be targeted with ablation to treat arrythmias."

Keep reading... Show less

Pall Corporation's new Supralon Filter Element Advances Equipment Protection and Reduces Energy Costs

- Pall Corporation, a leader in filtration, separation and purification technology and a Danaher operating company, launched the new Supralon TM hydraulic and lube oil filter element range, a direct upgrade for Pall's Coralon ® Ultipor ® and Red1000 series filters. Supralon filter elements incorporate a new pack construction with filter media utilizing stress-resistant technology (SRT) and showcasing anti-static properties, which ultimately help protect and prolong the life of equipment in hydraulic and lube oil applications.

Keep reading... Show less

ACELYRIN Appoints Melanie Gloria as Chief Operating Officer

- ACELYRIN, INC., a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates, today announced the appointment of Melanie Gloria BSN, as the company's chief operating officer (COO). In this role, Ms. Gloria will oversee business operations across the company.

Keep reading... Show less

Latest Press Releases

Related News

×